UPDATE: Oppenheimer Starts 9 Meter Biopharma (NMTR) at Outperform Citing 3 Value Drivers

January 28, 2021 4:13 PM EST
Get Alerts NMTR Hot Sheet
Price: $1.15 -3.36%

Rating Summary:
    4 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 17 | Down: 14 | New: 42
Trade Now! 
Join SI Premium – FREE
(Updated - January 29, 2021 8:20 AM EST)

Oppenheimer analyst Kevin DeGeeter initiates coverage on 9 Meter Biopharma (NASDAQ: NMTR) with a Outperform rating and a price target of $6.00 citing 3 drivers:
1) potential of NM-002 to recognize 2029 revenues of $725M+ from patients with short bowel syndrome (SBS)
2) opportunity to build GI-focused commercial organization to fully leverage value of NM-002 and other products
3) expectation NMTR will remain active in acquiring GI (gastrointestinal) products.

The analyst stated "Our model calls for the company to commercialize NM-002 in the US and the EU in 2024 with 2029 sales of $727M based primarily on its convenient twice-monthly dosing and the opportunity to reduce frequency and severity of diarrhea. We believe many investors may be overlooking the opportunity for NM-002 to capture meaningful market share in patients not on parenteral support, a market not addressed by Takeda's Gattex."

For an analyst ratings summary and ratings history on 9 Meter Biopharma click here. For more ratings news on 9 Meter Biopharma click here.

Shares of 9 Meter Biopharma closed at $1.11 yesterday.

You May Also Be Interested In

Related Categories

Analyst Comments, Hot New Coverage, New Coverage